Investigational drug · Phase 2
ALN-4324
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes Mellitus (T2DM), Obese or Overweight Healthy Volunteers.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "ALN-4324"
First trial start
2025
Mar 3, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALN-4324", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes Mellitus (T2DM)
- Obese or Overweight Healthy Volunteers
Approved drugs for the same conditions: Type 2 diabetes · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "ALN-4324" as an intervention, largest first.
- A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DMPivotal-lookingActive, not recruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT06845202 · 105 participants · Start Mar 3, 2025 · Primary completion Aug 31, 2027
Drug: ALN-4324; Placebo · For: Obese or Overweight Healthy Volunteers; Type 2 Diabetes Mellitus (T2DM)
Sites: Montclair, California; Washington D.C., District of Columbia; Miami, Florida · 22 sites in all
- A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes MellitusActive, not recruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07465224 · 24 participants · Start Jan 15, 2026 · Primary completion May 28, 2027
Drug: ALN-4324; Placebo · For: Type 2 Diabetes Mellitus (T2DM)
Sites: Chula Vista, California
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Type 2 Diabetes Mellitus (T2DM)
- BofanglutideGZR18, BofanglutidaPhase 311 trials
Gan & Lee Pharmaceuticals. · Type 2 Diabetes Mellitus (T2DM), Obstructive Sleep Apnea (OSA), Obesity/Overweight in Adult
- MWN109 1Phase 36 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- MWN109 2Phase 36 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- MWN109 3Phase 35 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- BGM0504 AdministeredPhase 32 trials
BrightGene Bio-Medical Technology Co., Ltd. · Type 2 Diabetes Mellitus (T2DM)
- AD-233APhase 31 trial
Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)
- AD-233BPhase 31 trial
Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)
- AD-233CPhase 31 trial
Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Alnylam Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.